Remove Clinical Trials Remove DEA Remove Patients Remove Treatment
article thumbnail

Final Phase of MDMA Clinical Trials Shows Drug Is 90% Effective at Treating PTSD

SpeedWeed

A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. For this study, researchers recruited 90 patients suffering from severe, chronic PTSD. Image via. This promising new study is helmed by Rick Doblin, Ph.D.

article thumbnail

DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington’s Disease Drug Development

Cannabis Law Report

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). Orphan Drug Designation?

DEA 66
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

DEA Seeks to Increase Quota of Cannabis and Psilocybin for Research Purposes

SpeedWeed

The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. Some states in the U.S.

DEA 52
article thumbnail

Emerge Law Group (OR): PSILOCYBIN THERAPY FOR PATIENTS WITH ADVANCED ILLNESS IN OREGON

Cannabis Law Report

One of the known beneficial uses of psilocybin is as a palliative care tool for patients with advanced illness who suffer from anxiety and/or depression. A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions.

Therapy 52
article thumbnail

AIMS v. Garland: A Disappointment for Psilocybin Advocates, but Progressive Policy May Still be on the Horizon

Cannabis Law Report

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). Background.

DEA 52
article thumbnail

Understanding the Current Legal Status of Psychedelics in the United States

Cannabis Law Report

The first path, that of traditional medicine, currently offers patients limited options. The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. 2022 Active FDA Clinical Trials and State-Regulated Systems.

article thumbnail

Senators Call For Report On State Of Psychedelic Research

Cannabis Law Report

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. Defining Psychedelics.